Screening for Inherited Heart Disease
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999
Trial Information
Current as of January 15, 2025
Completed
Keywords
ClinConnect Summary
Patients with hypertrophic cardiomyopathy (HCM) and other inherited cardiac diseases are being studied under several research protocols to determine their pathogenesis and clinical manifestations. The purpose of this protocol is to determine the eligibility of patients with known or suspected inherited heart conditions for our research protocols.
Gender
ALL
Eligibility criteria
- • INCLUSION CRITERIA
- • Subjects and family members known or suspected to have inherited a cardiac disease such as HCM.
- • EXCLUSION CRITERIA
- • Patients with cardiac conditions that are not known to be inherited.
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials